Understanding views of patients on biologics for psoriasis amid the COVID‐19 pandemic

Pandher, Karan; Porter, Caroline L; Patel, Hiral S.; Huang, William W.; Feldman, Steven R.

doi:10.1111/jdv.17091

Cited by 2 publications

(1 citation statement)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[ 52 ] This, as well as flares in disease, may be explained by diminished access to tertiary dermatology centers responsible for the initiation of biological agents[ 53 ] as well as patients fearing the initiation or continuation of immunosuppressive agents. [ 54 ] Evidence suggests that treatment of psoriasis with biological drugs should not be interrupted[ 55 ] even in areas where the pandemic is rife. [ 56 ] In fact, results from a global-registry-based study suggest that patients on biologic agents do comparatively better than patients on other systemic therapies, having a lower risk of being hospitalized from COVID-19-related complications.…”

Section: Discussionmentioning

confidence: 99%

Clinical Dermatology and COVID-19 Pandemic

Mintoff

Chatterjee

Podder

et al. 2021

Indian Journal of Dermatology

View full text Add to dashboard Cite

The coronavirus disease of 2019 (COVID-19) pandemic has radical repercussions on every aspect of medical science, including dermatology. The magnitude of the impact on clinical dermatology cannot be overemphasized. Dermatologists have been forced to modify and reconsider the way they consult patients. Teledermatology has come up in a big way, with most of the clinicians resorting to technology and software-based consultations. Management of different dermatological conditions like papulosquamous disorders, vesiculobullous disorders, malignancies, etc., needs to be modified as per the different recommendations proposed by expert panels. This review is an attempt to highlight the impact of this destructive pandemic on various aspects of clinical dermatology.

show abstract

Section: Discussionmentioning

confidence: 99%

Clinical Dermatology and COVID-19 Pandemic

Mintoff

Chatterjee

Podder

et al. 2021

Indian Journal of Dermatology

View full text Add to dashboard Cite

show abstract

Skin Manifestations in Psoriatic and HS Patients in Treatment with Biologicals during the COVID-19 Pandemic

Rosi

Fastame

Cesare

et al. 2021

JCM

View full text Add to dashboard Cite

The Coronavirus Disease 2019 (COVID-19) pandemic, a global public health emergency, has changed dermatology practice and daily routine in just under two years. Much has been written in the literature about COVID-19-associated skin manifestations. Nevertheless, much less has been written regarding skin manifestations in patients affected by severe immune-mediated skin diseases, e.g., psoriasis and hidradenitis suppurativa, undergoing biological treatment during the COVID-19 outbreak. Thus, the aim of this article is to provide the reader with an overview of the cutaneous manifestations during the COVID-19 pandemic in this subset of patients.

show abstract

Understanding views of patients on biologics for psoriasis amid the COVID‐19 pandemic

Cited by 2 publications

References 7 publications

Clinical Dermatology and COVID-19 Pandemic

Clinical Dermatology and COVID-19 Pandemic

Skin Manifestations in Psoriatic and HS Patients in Treatment with Biologicals during the COVID-19 Pandemic

Contact Info

Product

Resources

About